Articles tagged "Vascular disease"

2015 American Transplant Congress
Survival of Patients With Peripheral Vascular Disease on Kidney Waitlist and After Transplantation: An Analysis of the United State Renal Data System
A. Brar,¹ D. Stefanov,³ R. Jindal,² N. Sumrani,⁴ D. John,⁴ F. Tedla,¹ M. Salifu.¹
¹Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY; ²Department of Surgery, Walter Reed National Military Medical Center, Uniformed Services University of Health Sciences, Bethesda, MD; ³Division of Research, SUNY Downstate School of Medicine, Brooklyn, NY; ⁴Department of Surgery, SUNY Downstate Medical Center, Brooklyn, NY.
Introduction: There is lack of information whether waitlisted dialysis patients with peripheral vascular disease (PVD) benefit from kidney transplantation.Methods: We used a cohort of USRDS…
2015 American Transplant Congress
Conditioning of Mesenchymal Stromal Cells With mTOR Inhibitor Enhances Regenerative Properties of Secretome and Attenuates Vascular Calcification
B. Hegner,¹ C. Kurth,¹ T. Schaub,¹ C. Lange,² D. Dragun.¹
¹Clinic for Nephrology and Intensive Care Medicine, Charité University Hospital, Berlin, Germany; ²Department of Cell and Gene Therapy, University Medical Center Eppendorf, Hamburg, Germany.
Similar to patients with chronic kidney disease, recipients of kidney transplants are a high-risk population for cardiovascular events due to arterial media calcification in particular…
2015 American Transplant Congress
Progression of Coronary Artery Disease in High-Risk Patients Undergoing Renal Transplantation
R. Corbett, N. Kumar, C. Baker, D. Moutzouris, M. Willicombe, J. Galliford, A. McLean, N. Duncan, D. Taube.
Imperial College Renal and Transplant Centre, London, United Kingdom.
Asymptomatic coronary artery disease [CAD] is common in patients with end-stage renal disease [ESRD]. While coronary revascularization prior to transplantation is associated with improved patient…
2015 American Transplant Congress
Evaluating the Benefits of Everolimus on Cardiac Allograft Vasculopathy: Further Evidence from Results of Imputations for Missing IVUS Data from A2310 Study
P. Lopez,¹ G. Dong,² Z. Wang.²
¹Novartis Pharma AG, Basel, Switzerland; ²Novartis Pharmaceuticals, East Hanover, NJ; ³Novartis Pharmaceuticals, East Hanover, NJ.
Purpose: A2310 IVUS study showed that everolimus (EVR) provides cardiac allograft vasculopathy (CAV) benefit compared to mycophenolate mofetil (MMF) by assessing the mean change in…
2015 American Transplant Congress
High Atherosclerotic Burden in Pediatric Lung Transplant Recipients
A. Melk,¹ D. Thurn-Valsassina,¹ N. Schwerk,² F. Brinkmann,² C. Mueller.²
¹Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany; ²Department of Pediatric Pneumology and Neonatology, Hannover Medical School, Hannover, Germany.
Purpose: Pediatric lung transplant patients have been reported to have an increased incidence of hypertension. This incidence might be caused by the treatment with calcineurin…
2015 American Transplant Congress
Investigating Role of Early VTE Chemoprophylaxis in Kidney Transplant
D. Kendrick,¹ E. Kudlaty,¹ A. Kim,¹ P. Moorehead,¹ J. Augustine,² E. Sanchez,² V. Kashyap,¹ K. Woodside.²
¹Vascular Surgery, University Hospitals-Case Medical Center, Cleveland, OH; ²Transplant Institute, University Hospitals-Case Medical Center, Cleveland, OH.
Objective: Our objective was to determine whether the rate of venothromboembolic events (VTE) varied with early versus delayed prophylaxis administration. Associated bleeding complications were also…